N-ethylthiophene-2-sulfonamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: N-ethylthiophene-2-sulfonamide
• 化学式: C₆H₉NO₂S₂
• mdl: MFCD02135293
• 分子量: 191.275
• InChiKey: ZSJVAIJAXKMYGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  82.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-ethylthiophene-2-sulfonamide 在 tetrakis(actonitrile)copper(I) hexafluorophosphate 、 2,2'-联喹啉 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 6.0h， 生成
  参考文献：
  名称：

  铜催化的三氟甲基化和芳族磺酰基基团链烯烃的环化反应，用于构建1,2-苯并噻嗪烷二氧化物类化合物。

  摘要：

  多才多艺的系统：已开发出一种有效的铜催化串联的三氟甲基化/电子缺陷型芳香环的环。该方法提供了一种在温和的条件下合成三氟甲基化的1,2-苯并噻嗪烷二氧化物的强大而直接的方法（请参见方案）。通过一系列动力学实验和同位素标记研究研究了该机制。

  DOI：

  10.1002/chem.201303623
• 作为产物：
  描述：

  2-噻吩磺酰氯 、 乙胺盐酸盐 在 potassium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.0h， 生成 N-ethylthiophene-2-sulfonamide
  参考文献：
  名称：

  铜催化的三氟甲基化和芳族磺酰基基团链烯烃的环化反应，用于构建1,2-苯并噻嗪烷二氧化物类化合物。

  摘要：

  多才多艺的系统：已开发出一种有效的铜催化串联的三氟甲基化/电子缺陷型芳香环的环。该方法提供了一种在温和的条件下合成三氟甲基化的1,2-苯并噻嗪烷二氧化物的强大而直接的方法（请参见方案）。通过一系列动力学实验和同位素标记研究研究了该机制。

  DOI：

  10.1002/chem.201303623

文献信息

• Novel high affinity quinoline-based kinase ligands
  申请人：Deng Yongqi

  公开号：US20080045568A1

  公开（公告）日：2008-02-21

  Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

  基于喹啉的细胞周期蛋白依赖激酶2抑制剂，包括这些抑制剂的组合物，以及使用这些抑制剂和抑制剂组合物的方法。这些抑制剂和包括它们的组合物对治疗疾病或疾病症状有用。该发明还提供了制备CDK-2抑制剂化合物的方法，抑制CDK-2的方法，以及治疗疾病或疾病症状的方法。
• ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080317712A1

  公开（公告）日：2008-12-25

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20090005387A1

  公开（公告）日：2009-01-01

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：SUN Ying

  公开号：US20090098085A1

  公开（公告）日：2009-04-16

  The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
• US7084170B2
  申请人：——

  公开号：US7084170B2

  公开（公告）日：2006-08-01